HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

A pilot trial of intravenous pamidronate for chronic low back pain.

Abstract
Intravenous (i.v.) bisphosphonates relieve pain in conditions such as Paget's disease of bone, metastatic bone disease, and multiple myeloma. Based on positive findings from a prior case series, we conducted a randomized placebo-controlled study to assess the analgesic effect of i.v. pamidronate in subjects with chronic low back pain (CLBP) and evidence of degenerative disease of the spine. Four groups of 11 subjects (7 active, 4 placebo) were enrolled at escalating dose levels of 30, 60, 90, and 180 mg pamidronate (the latter administered as two 90 mg infusions). Primary outcomes were safety and change from baseline in average daily pain scores, recorded at 1, 2, 3, and 6 months postinfusion using electronic diaries. Secondary outcomes included responder rate, daily worst pain, and pain-related interference with daily function. There were no pamidronate-related serious adverse events or other significant safety findings. A statistically significant overall treatment difference in pain scores was observed, with clinically meaningful effects persisting for 6 months in the 180 mg pamidronate group. Least squares mean changes in daily average pain score were -1.39 (SE=0.43) for placebo, and -1.53 (0.71), -1.26 (0.81), -1.42 (0.65), and -4.13 (0.65) for pamidronate 30, 60, 90, and 180 mg, respectively (P=0.012 for pamidronate 180 mg vs placebo). The proportion of responders, changes in worst pain, and pain interference with daily function were also significantly improved for pamidronate 180 mg compared with placebo. In conclusion, i.v. pamidronate, administered as two 90 mg infusions, decreased pain intensity for 6 months in subjects with CLBP.
AuthorsMarco Pappagallo, Brenda Breuer, Hung-Mo Lin, James B Moberly, Julia Tai, Christopher Noto, Angela Sanchez, Paolo L Manfredi
JournalPain (Pain) Vol. 155 Issue 1 Pg. 108-17 (Jan 2014) ISSN: 1872-6623 [Electronic] Netherlands
PMID24060707 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Bone Density Conservation Agents
  • Diphosphonates
  • pamidronate
Topics
  • Administration, Intravenous
  • Adult
  • Aged
  • Bone Density Conservation Agents (therapeutic use)
  • Chronic Pain (complications, drug therapy)
  • Diphosphonates (therapeutic use)
  • Disability Evaluation
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Low Back Pain (complications, drug therapy)
  • Male
  • Middle Aged
  • Pain Measurement
  • Pilot Projects
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: